Bellicum Pharmaceuticals (BLCM) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Bellicum Pharmaceuticals, Inc. is undergoing a significant transformation as it executes its liquidation and dissolution plan, leading to the resignation of all board directors except for Mr. Fair, who remains the sole director. Amidst these changes, the company appointed Dave Maggio as the new CEO, leveraging his extensive experience in financial advisory and corporate finance, particularly with small to mid-market companies. The company also extended its consulting agreement with former CEO Mr. Fair to support the transition. These strategic moves aim to navigate the dissolution process smoothly, reflecting the company’s commitment to a structured and professional approach.
For further insights into BLCM stock, check out TipRanks’ Stock Analysis page.
